Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Resistentia Pharmaceuticals
company
About
Resistentia Pharmaceuticals develops immunotherapeutic products for allergic asthma and inflammatory disorders.
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $13.96M
- Industries
- Biotechnology,Health Care,Medical Device,Therapeutics
- Founded date
- Jan 1, 1998
- Operating Status
- Active
Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$13.96M
Resistentia Pharmaceuticals has raised a total of
$13.96M
in funding over 2 rounds. Their latest funding was raised on
Sep 26, 2006 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 26, 2006 | Series C | $13.96M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Resistentia Pharmaceuticals is funded by 1 investors.
BankInvest Biomedical Venture
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
BankInvest Biomedical Venture
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
